In a more robust dataset of 1470 AML patients, NGS was used to analyze 17 potentially actionable genes (ALK, CSF1R, FGFR1/2/3, FLT3, IDH1/2, JAK2, KDR, KRAS/NRAS, NPM1, PDGFRA, PTPN11, RET, and TP53), because these genes are directly or indirectly targetable with standard (with 6% of patients receiving off-label agents) or investigational agents (53% of these patients were enrolled in clinical trials) [183]. Here, TP53 is linked to acute myeloid leukemia.